Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (6665)	1/11/1999 6:57:00 AM
From: Anthony Wong	Read Replies (2) \| Respond to of 9523

Merck & Co. Says Arthritis Drug Does Not Cause Ulcers, WSJ Says Bloomberg News January 11, 1999, 4:47 a.m. ET London, Jan. 11 (Bloomberg) -- Merck & Co. says its new arthritis drug, Vioxx, does not cause gastrointestinal problems, allowing it to be marketed as a wide-ranging pain killer, the Wall Street Journal Interactive edition reported, citing no sources. Vioxx is likely to be approved in late Spring by the U.S Food and Drug administration, the newspaper said. Vioxx is a new type of drug, called a Cox-2 inhibitor, that Wall street analysts believe could generate world-wide combined sales of $5 billion by 2003, the newspaper reported. Monsanto Co., a leading agricultural products company expanding into pharmaceuticals, said Jan. 4 it will sell its newly approved Celebrex arthritis drug at prices as low as or lower than comparable brand-name painkillers. (The Wall Street Journal Interactive Edition www.wsj.com) --Will Wareing in the London newsroom (44 171) 330 7699/cp